What is Johnson & Johnson's medtech — marketable security, realized gain (loss)?

Johnson & Johnson (JNJ) reported medtech — marketable security, realized gain (loss) of $50.00M in Q4 2025.

What does medtech — marketable security, realized gain (loss) mean?

The net profit or loss recognized from selling investment securities held by the medical technology division.

Business Segments · Marketable Security, Realized Gain (Loss)

MedTech — Marketable Security, Realized Gain (Loss)

Johnson & Johnson MedTech — Marketable Security, Realized Gain (Loss) remained flat by 0.0% to $50.00M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryOther

SignalHigher is better

VolatilityVolatile

First reportedQ1 2025

Last reportedQ4 2025

Rolls up toRealized Gain (Loss) on Marketable Securities (Excl. OTTI)

How to read this metric

Positive values indicate successful investment exits or portfolio optimization, while negative values reflect losses realized during market downturns or strategic rebalancing.

Detailed definition

This metric captures the net realized gains or losses resulting from the sale or disposal of marketable securities held...

Peer comparison

Similar to other large-cap healthcare firms, this metric tracks non-core financial income that can fluctuate based on broader capital market conditions.

Metric ID: jnj_segment_medtech_marketable_security_realized_gain_loss

Historical Data

1 years

	FY'25
Value	$200.00M

Similar Metrics at Other Companies

StrykerSYK View metric

MedtronicMDT View metric

SalesforceCRM View metric

StrykerSYK View metric

McKessonMCK View metric

Frequently Asked Questions

What is Johnson & Johnson's medtech — marketable security, realized gain (loss)?: Johnson & Johnson (JNJ) reported medtech — marketable security, realized gain (loss) of $50.00M in Q4 2025.
What does medtech — marketable security, realized gain (loss) mean?: The net profit or loss recognized from selling investment securities held by the medical technology division.